Publication

Cost-effectiveness of increasing bisphosphonates adherence for osteoporosis in community pharmacies

Van Boven, J. F. M., Oosterhof, P., Hiddink, E. G., Stuurman-Bieze, A. G. G., Postma, M. J. & Vegter, S., 1-Nov-2011, In : Value in Health. 14, 7, p. 310 1 p.

Research output: Contribution to journalMeeting AbstractAcademic

OBJECTIVES: Increasing real-life adherence to bisphosphonates therapy is important to achieve the clinical benefits of reducing fractures reported in randomized clinical trials (RCTs). The aim of this pharmacoeconomic analysis was to determine the cost-effectiveness of a pharmaceutical care intervention program in community pharmacies, aimed to increase bisphosphonates adherence for the prevention of osteoporotic fractures. METHODS: A decision analytical model was constructed with a time horizon of three years, discounting at 4.0% and 1.5% annually for costs and effects, respectively. A Dutch healthcare provider's perspective was adopted. Adherence and efficacy data were gathered from a Dutch pharmaceutical care program in community pharmacies (the MeMO intervention). The association between bisphosphonate adherence and osteoporotic fractures was modelled using Dutch clinical studies. Recent and upcoming reimbursement policy changes in The Netherlands were modelled with a scenario of therapeutic substitution, characterized by drastically lower drug prices. RESULTS: Adherence to bisphosphonates therapy in The Netherlands was 68.3%. The pharmaceutical care intervention program increased bisphosphonates adherence to 83.9% (P
Original languageEnglish
Pages (from-to)310
Number of pages1
JournalValue in Health
Volume14
Issue number7
Publication statusPublished - 1-Nov-2011

    Keywords

  • bisphosphonic acid derivative, community, pharmacy, cost effectiveness analysis, osteoporosis, pharmaceutical care, fragility fracture, therapy, policy, fracture, cost control, Netherlands, human, quality adjusted life year, model, health care personnel, clinical study, reimbursement, clinical trial (topic), pharmacoeconomics, prevention, drug therapy

View graph of relations

ID: 20494750